Author details

Full Name

Isabel Arrillaga-Romany

Affiliation

ORCID

Career Start Year

2008

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37400643	Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.	Nat Med	2024
36526609	IDH-mutant glioma: A new IDH1 inhibitor moves forward.		2023
37584601	Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.	Cancer Discov	2023
37722087	Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.	J Clin Oncol	2023
37467494	Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.	Blood	2023
37402650	Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.	Neuro Oncol	2023
36648934	Challenges and Opportunities for Clinical Trials in Patients With Glioma.	JAMA Neurol	2023
36823302	Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.	Nat Med	2023
37327319	Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients.	Clin Cancer Res	2023
37488293	Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.	Nat Med	2023
34751617	Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma.	Radiology	2022
35443045	Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care.	Oncologist	2022
36471067	The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.	Nat Genet	2022
35289329	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.	Nat Commun	2022
35239963	Enhancing demethylation-induced differentiation in IDH-mutant glioma.	Neuro-Oncology	2022
32882013	TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.	Neuro Oncol	2021
33626257	Case 6-2021: A 65-Year-Old Man with Eye Pain and Decreased Vision.	New England Journal of Medicine	2021
34131648	MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma.	Neurooncol Adv	2021
33646525	Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.	Journal of Neuro-Oncology	2021
32923886	Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent Glioblastoma.	JCO Precis Oncol	2020
31702782	Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.	Neuro Oncol	2020
30668823	Accelerated progression of IDH mutant glioma after first recurrence.	Neuro Oncol	2019
32914038	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma.	JCO Precis Oncol	2019
30559168	Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.	Clin Cancer Res	2019
30742122	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.	Nat Med	2019
30681891	Performance of a Hospital Pathway for Patients With a New Single Brain Mass.	J Oncol Pract	2019
31385986	Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series.	Neurooncol Pract	2018
30072074	Neurologic Complications of Systemic Anticancer Therapy.	Neurologic Clinics	2018
29662077	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.	Nat Commun	2018
29660006	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.	Neuro Oncol	2018
29108308	A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.	Oncotarget	2017
28834486	Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.	N Engl J Med	2017
24320142	Current status of antiangiogenic therapies for glioblastomas.	Expert Opinion on Investigational Drugs	2014
25363007	Antiangiogenic therapies for glioblastoma.	CNS oncology	2014
23361490	Imaging findings in cancer therapy-associated neurotoxicity.	Seminars in Neurology	2012
22810132	Neurologic complications of cancer drug therapies.	CONTINUUM Lifelong Learning in Neurology	2012
20555311	Modulatory effects of modafinil on neural circuits regulating emotion and cognition.		2010
18445218	Long-lasting alteration in mesocorticolimbic structures after repeated social defeat stress in rats: time course of mu-opioid receptor mRNA and FosB/DeltaFosB immunoreactivity.	European Journal of Neuroscience	2008